Home › Clovis Oncology's Phase 2 Studies of Rucaparib in Ovarian Cancer...
 

Keywords :   


Clovis Oncology's Phase 2 Studies of Rucaparib in Ovarian Cancer...

2015-05-30 21:49:00| Logistics - Topix.net

Clovis Oncology today announced updated Phase 2 results from two ongoing clinical studies with rucaparib: ARIEL2 and Study 10. Rucaparib is the Company's investigational oral, potent, small molecule inhibitor of PARP1 and PARP2 being developed for the treatment of advanced ovarian cancer, specifically in patients with BRCA mutations and other DNA repair deficiencies beyond BRCA, commonly referred to as "BRCA-like." Updated data from the ARIEL2 study in 204 patients with advanced ovarian cancer are being presented Monday in an oral presentation by Professor Iain McNeish at the 2015 American Society of Clinical Oncology annual meeting in Chicago.

Tags: studies phase cancer ovarian

Category:Transportation and Logistics

Latest from this category

All news
06.10Hurricane Leslie Graphics
06.10Hurricane Leslie Forecast Discussion Number 16
06.10Summary for Hurricane Leslie (AT3/AL132024)
06.10Hurricane Leslie Public Advisory Number 16
06.10Hurricane Leslie Forecast Advisory Number 16
06.10Hurricane Leslie Wind Speed Probabilities Number 16
06.10Hurricane Kirk Graphics
06.10Tropical Storm Milton Graphics
Transportation and Logistics »
06.10Ex-cabinet secretary says 200,000 job is underpaid
06.10Hurricane Leslie Graphics
06.10Hurricane Leslie Forecast Discussion Number 16
06.10Hurricane Leslie Wind Speed Probabilities Number 16
06.10Hurricane Leslie Forecast Advisory Number 16
06.10Hurricane Leslie Public Advisory Number 16
06.10Summary for Hurricane Leslie (AT3/AL132024)
06.10Hurricane Kirk Graphics
More »